WallStSmart

Kestra Medical Technologies, Ltd. Common Stock (KMTS)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 3397% more annual revenue ($3.33B vs $95.13M). WST leads profitability with a 17.0% profit margin vs -138.3%. WST earns a higher WallStSmart Score of 59/100 (C).

KMTS

Avoid

28

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -1.47

WST

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for KMTS.

WSTSignificantly Overvalued (-47.4%)

Margin of Safety

-47.4%

Fair Value

$167.06

Current Price

$349.42

$182.36 premium

UndervaluedFair: $167.06Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

KMTS2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
66.2%10/10

Revenue surging 66.2% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

KMTS4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.34B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-50.3%2/10

ROE of -50.3% — below average capital efficiency

Free Cash FlowQuality
$-28.38M2/10

Negative free cash flow — burning cash

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

PEG RatioValuation
3.022/10

Expensive relative to growth rate

P/E RatioValuation
45.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : KMTS

The strongest argument for KMTS centers on Revenue Growth, Debt/Equity. Revenue growth of 66.2% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : KMTS

The primary concerns for KMTS are EPS Growth, Market Cap, Return on Equity.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 45.1x leaves little room for execution misses.

Key Dynamics to Monitor

KMTS profiles as a hypergrowth stock while WST is a mature play — different risk/reward profiles.

KMTS is growing revenue faster at 66.2% — sustainability is the question.

WST generates stronger free cash flow (81M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (59/100 vs 28/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Kestra Medical Technologies, Ltd. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Kestra Medical Technologies, Ltd. is a wearable medical device and digital healthcare company. The company is headquartered in Kirkland, Washington.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?